v3.26.3
Segment
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Segment
The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic tests and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discretely available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discrete operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discrete operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.
Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands of dollars):

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue:
Testing revenue$146,419 $127,756 $427,171 $357,328 
Product revenue4,626 3,301 12,163 10,479 
Biopharmaceutical and other revenue709 815 1,812 8,702 
Total revenue151,754 131,872 441,146 376,509 
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense14,807 14,766 40,968 43,134 
Sample collection expense3,707 3,078 10,638 9,398 
Compensation expense10,839 6,273 30,501 17,906 
Other cost of testing revenue (1)5,878 6,456 16,699 14,017 
Allocation of facilities and IT expenses3,246 3,204 9,286 9,989 
Total cost of testing revenue38,477 33,777 108,092 94,444 
Cost of product revenue:
Product costs2,128 1,050 5,513 1,864 
License fees and royalties420 257 1,069 888 
Other cost of product revenue (2)214 1,672 579 2,980 
Allocation of facilities and IT expenses4 36 11 454 
Total cost of product revenue2,766 3,015 7,172 6,186 
Cost of biopharmaceutical and other revenue:
Compensation expense— 426 — 3,318 
Other cost of biopharmaceutical and other revenue (3)142 612 357 3,118 
Allocation of facilities and IT expenses— 53 — 925 
Total cost of biopharmaceutical and other revenue142 1,091 357 7,361 
Intangible asset amortization - cost of revenue3,265 2,707 8,713 7,959 
Gross profit107,104 91,282 316,812 260,559 
Operating expenses:
Research and development:
Compensation expense17,819 9,028 50,185 27,840 
Direct research and development expense5,396 3,512 13,380 10,946 
Other research and development expenses (4)6,925 1,586 19,174 5,278 
Allocation of facilities and IT expenses2,019 1,855 5,960 5,901 
Total research and development32,159 15,981 88,699 49,965 
Selling and marketing:
Compensation expense20,384 16,977 59,929 52,214 
Direct marketing expense2,137 1,376 6,299 3,564 
Other selling and marketing expenses (5)4,755 3,332 13,874 10,880 
Allocation of facilities and IT expenses1,376 2,770 3,969 7,567 
Total selling and marketing28,652 24,455 84,071 74,225 
General and administrative:
Compensation expense19,642 20,688 54,324 62,121 
Other general and administrative expenses (6)16,305 14,508 45,327 56,132 
Allocation of facilities and IT expenses(6,645)(7,918)(19,226)(24,836)
Total general and administrative29,302 27,278 80,425 93,417 
Impairment of assets— — — 20,505 
Intangible asset amortization - operating expenses422 622 1,422 1,865 
Other (income) loss, net(4,553)4,057 (15,424)(6,985)
Income tax provision (benefit)(10,381)(248)(8,081)2,363 
Net income$31,503 $19,137 $85,700 $25,204 
________________

(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.
(2)Other cost of product revenue includes contract manufacturing fees, license fees and royalties, depreciation and amortization and other expenses.
(3)Other cost of biopharmaceutical and other revenue includes professional fees, information technology expense, depreciation and amortization and other expenses.
(4)Other research and development expenses include depreciation and amortization and other expenses.
(5)Other selling and marketing expenses include travel, entertainment, conference and other expenses.
(6)Other general and administrative expenses include professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.